NetworkNewsBreaks – Neothetics, Inc. (NASDAQ: NEOT) Shares Sink to New Low on Disappointing Phase 2 Study of LIPO-202
Shares of Neothetics (NASDAQ: NEOT) plummeted more than 69% to a new 52-week low of $0.70 after the specialty pharmaceutical company said its fat reduction candidate, LIPO-202-CL-31, failed to demonstrate improvement on any efficacy measurements or separation from placebo. LIPO-202 continued to show a benign safety profile. “We are determining the path forward for the company,” Kim Kamdar, Ph.D., a member of Neothetics’ operating committee and board of directors, stated in the news release. “Our primary objective is to maximize value for our shareholders, and we will be expeditious and diligent in deciding next steps. We will share our future…







